Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 7—July 2019

Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015

Maroya Spalding WaltersComments to Author , Julian E. Grass, Sandra N. Bulens, Emily B. Hancock, Erin C. Phipps, Daniel Muleta, Jackie Mounsey, Marion A. Kainer, Cathleen Concannon, Ghinwa Dumyati, Chris Bower, Jesse Jacob, P. Maureen Cassidy, Zintars Beldavs, Karissa Culbreath, Walter E. Phillips, Dwight J. Hardy, Roberto L. Vargas, Margret Oethinger, Uzma Ansari, Richard Stanton, Valerie Albrecht, Alison Laufer Halpin, Maria Karlsson, J. Kamile Rasheed, and Alexander Kallen
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.S. Walters, J.E. Grass, S.N. Bulens, U. Ansari, R. Stanton, V. Albrecht, A.L. Halpin, M. Karlsson, J.K. Rasheed, A. Kallen); New Mexico Emerging Infections Program, Santa Fe, New Mexico, USA (E.B. Hancock, E.C. Phipps); University of New Mexico, Albuquerque, New Mexico, USA (E.B. Hancock, E.C. Phipps, K. Culbreath); Tennessee Department of Public Health, Nashville, Tennessee, USA (D. Muleta, J. Mounsey, M.A. Kainer); University of Rochester, Rochester, New York, USA (C. Concannon, G. Dumyati, D.J. Hardy); Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA (C. Bower); Atlanta Research and Education Foundation, Decatur (C. Bower); Georgia Emerging Infections Program, Atlanta (C. Bower, J. Jacob); Emory University School of Medicine, Atlanta (J. Jacob); Oregon Health Authority, Portland, Oregon, USA (P.M. Cassidy, Z. Beldavs); TriCore Reference Laboratories, Albuquerque (K. Culbreath); Tristar Centennial Medical Center, Nashville (W.E. Phillips, Jr.); Rochester Regional Health, Rochester (R.L. Vargas); Providence Health and Services, Renton, Washington, USA (M. Oethinger)

Main Article

Table 2

Carbapenem-resistant Pseudomonas aeruginosa patient demographics and clinical characteristics, United States, July–October 2015*

Patient demographics N = 274
F 114 (41.6)
M 160 (58.4)
Median age, y (range) 66 (<1–98)
Age group, y
0–18 9 (3.3)
19–49 57 (20.8)
50–64 67 (24.5)
65–79 91 (33.2)
>80 50 (18.2)
White ethnicity
181/226 (80.1)
Underlying clinical conditions† N = 262
None 6 (2.3)
Chronic obstructive pulmonary disease 95 (36.3)
Diabetes 90 (34.4)
Chronic renal insufficiency 59 (22.5)
Decubitus ulcer 55 (21.0)
Congestive heart failure 51 (19.5)
Neurologic problems 49 (18.7)
Urinary tract problems/abnormalities 49 (18.7)
Obesity 44 (16.8)
Stroke 40 (15.3)
Dementia 37 (14.1)
Hemiplegia/paraplegia 35 (13.4)
Chronic skin breakdown 29 (11.1)
Prolonged surgical wound 15 (51.7)
Burn 1 (3.4)
Other type of chronic skin breakdown 14 (48.3)
Peripheral vascular disease 27 (10.3)
Solid tumor (nonmetastatic) 27 (10.3)
Other underlying conditions‡ 125 (47.7)
Median CCI score (range) 2 (0–14)

*Values are no. (%) patients except as indicated. For patients with >1 incident case, demographics and clinical characteristics reflect those reported at the time of first incident case. CCI, Charlson Comorbidity Index.
†Total number of patients with a completed case report form and information available for underlying conditions.
‡Underlying conditions reported for <10% of patients are included in the other underlying conditions category: current smoker (n = 23), myocardial infarct (n = 18), metastatic solid tumor (n = 13), alcohol abuse (n = 10), chronic liver disease (n = 10), transplant recipient (n = 9), connective tissue disease (n = 8), chronic bronchiectasis (n = 6), liver failure (n = 6), hematologic malignancy (n = 5), spina bifida (n = 5), cystic fibrosis (n = 4), inflammatory bowel disease/Crohn’s disease (n = 3), peptic ulcer disease (n = 3), HIV (n = 1), and intravenous drug user (n = 1).

Main Article

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.